Ventricular Arrhythmias

Risks & contraindications

Comparisons

Background

Evidence quality

Highlighted claims

• Implantable cardioverter defibrillators treat ventricular arrhythmias after they occur but do not prevent them. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Sudden cardiac death accounts for up to 20% of all deaths in the Western world. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Beta-blockers are the only antiarrhythmic medication class proven to reduce mortality from ventricular arrhythmias in heart failure. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Despite current therapy, arrhythmia and death rates in heart failure with reduced ejection fraction remain around 5–10% per year. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Catheter ablation leaves up to one-third of patients with recurrent arrhythmias and has not demonstrated a mortality benefit in trials. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Patients with severe heart failure and recurrent ventricular arrhythmias have a poor prognosis, with mortality above 50% at 5 years. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia